0
New
New
2022
Aneurysmal Subarachnoid Hemorrhage Drugs Market

Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics, Other Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

✷  A04249
Pages: 180
Mar 2022 | 8059 Views
Author(s) : Suraj C sajeev , Onkar Sumant
Tables: 90
Charts: 51
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Aneurysmal Subarachnoid Hemorrhage Drugs Market

Request Now !

The global aneurysmal subarachnoid hemorrhage drugs market size was valued at $323.51 million in 2020, and is projected to reach $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030. Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the area around the brain. The major factors that drive the growth of the global aSAH drugs market include surge in geriatric population and increase in population suffering from hypertension. Furthermore, lifestyle changes such as alcohol consumption and smoking increase risk of aSAH, which, in turn, propel the market growth.

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the globe. The disease has forced a number of industries to shut their operations temporarily, including several sub-domains of healthcare. The COVID-19 pandemic led to disruptions in healthcare facilities. COVID-19 pandemic positively impacted key players in aSAH drugs market. Hemorrhagic cerebrovascular events, either due to aneurysmal rupture or spontaneous subarachnoid hemorrhage (SAH), are not rare in COVID-19. Several mechanisms such as coagulopathy, cytokine storm, viral endotheliopathy, hypertension, and immune modulation might play a role in the pathogenesis of SAH in COVID-19. Furthermore, during lockdown, patients faced difficulties with their ongoing treatment. However, community-dwelling individuals with disability were given special permission to go out for physical therapy and rehabilitation services. Moreover, patients suffering from aSAH had to switch to tele-medicine during the lockdown as they could not visit the hospitals.

Get more information on this report : Request Sample Pages

Hypertension is one of the major factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70.0 million American adults suffer from high blood pressure, of which the condition of only 52.0% is under control. Moreover, according to the Centers for Medicare and Medicaid Services the U.S. healthcare expenditures grew from 4.6% to $3.8 trillion in 2019 and accounted for 17.7% of gross domestic product (GDP). In addition, the federal government accounted for 29 % of total health expenditures, followed by households with 28.4%. State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

Furthermore, incidence of high blood pressure has increased, costing the U.S. $46.0 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.

In addition, increase in prevalence diseases such as stroke and hypertension and surge in geriatric population drive the growth of the aSAH drugs market. In addition, lifestyle changes, including increase in alcohol consumption and smoking rise the risk for aSAH, which, in turn, stimulates the market growth.

However, the associated side effects of drugs and medication taken during the treatment of aSAH restrain the aSAH drugs market share.

The aSAH drugs market is segmented on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

Aneurysmal Subarachnoid Hemorrhage Drugs Market
By Drug Class

Your browser does not support the canvas element.

The calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period

Get more information on this report : Request Sample Pages

Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market growth.

Aneurysmal Subarachnoid Hemorrhage Drugs Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure

Get more information on this report : Request Sample Pages

Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies, contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increased demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the demand for product. Moreover, China is expected to grow at high CAGR in, thereby making Asia-Pacific a aSAH drugs market opportunity.

The major companies profiled in this report include Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current aSAH drugs market trends, estimations, and dynamics of the aneurysmal subarachnoid hemorrhage drugs market analysis from 2020 to 2030 to identify the prevailing aneurysmal subarachnoid hemorrhage drugs market opportunities.
  • The aSAH Drugs Market analysis research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the aneurysmal subarachnoid hemorrhage drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global aSAH drugs industry trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments & Key Market Players

Segments Sub-segments
By Drug Class
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agents/Diuretics
  • Other Drugs
  • Opioid Analgesic

By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • South Africa
    • Rest of LAMEA

Key Market Players
  • Azurity Pharmaceuticals
  • Johnson and Johnson
  • medicure
  • NeurOp
  • orexo ab
  • Pfizer, Inc.
  • Pharmaxis, Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • teva pharmaceutical industries ltd.
  • Vitrais, Inc
 

Loading Table Of Content...


 
 

According to the analyst’s perspective, diseases such as hypertension and stroke constitute major proportion of health and economic concern across the globe; hence, the development of effective medication is the major necessity for their treatment.

The major factors that contribute to the market growth include change in lifestyle and rise in geriatric population. In addition, lifestyle changes that include surge in alcohol consumption and smoking rise the risk for aSAH, which accelerate the market growth. Along with this, surge in geriatric population are also prevailing the growth of the aneurysmal subarachnoid hemorrhage drugs market. However, associated side effects of the drugs are expected to restrain the market growth. In addition, need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage is expected to provide lucrative opportunities for the market growth.

North America is anticipated to dominate the aneurysmal subarachnoid hemorrhage drugs market throughout the forecast period, owing to increase in incidence of people suffering from hypertension, followed by Europe and Asia-Pacific.

Flash Sale
PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The Aneurysmal Subarachnoid Hemorrhage Market is currently growing at a CAGR of 3.6% from 2021-2030.

A. Drug types such as Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics which are off label drugs are used in treating Aneurysmal Subarachnoid Hemorrhage.

A. Estimated industry size of Aneurysmal Subarachnoid Hemorrhage Drugs Market is USD 323.5 Million in 2020

A. Largest regional market for Aneurysmal Subarachnoid Hemorrhage Drugs Market is North America.

A. Azurity Pharmaceuticals, Johnson and Johnson, MediCure, NeurOp, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Aneurysmal Subarachnoid Hemorrhage Drugs Market

Start reading instantly.
This Report and over 13,000+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $4,904
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,483
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,995  $8,796
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers